The Shift to Global Cardiovascular Risk Assessment
In preventive cardiology, clinical decisions are based on a patient’s overall cardiovascular risk rather than single lipid numbers. This approach evaluates multiple risk factors to estimate the probability of a cardiovascular event over time. The primary tool used for this assessment is the 10-year risk calculator for Atherosclerotic Cardiovascular Disease (ASCVD). This tool helps guide decisions about initiating preventive therapies, such as statins or blood pressure medications.
The Pooled Cohort Equations (PCE)
The Pooled Cohort Equations (PCE) were introduced in the 2013 ACC/AHA guidelines to estimate the 10-year risk of a first hard ASCVD event (defined as nonfatal myocardial infarction, coronary heart disease death, or fatal/nonfatal stroke) in adults aged 40 to 79. The calculator uses several clinical inputs:
- Age
- Sex
- Race (White, African American, or Other)
- Total Cholesterol and HDL-C levels, as measured on a lipid panel
- Systolic Blood Pressure
- Blood pressure-lowering medication use
- Diabetes status
- Smoking status
Based on the calculated percentage, patients are categorized into four risk groups: low risk (less than 5%), borderline risk (5% to less than 7.5%), intermediate risk (7.5% to less than 20%), and high risk (20% or greater).
Risk-Enhancing Factors
For patients categorized as intermediate or borderline risk, clinical decisions can be refined by evaluating “risk-enhancing factors.” These are clinical features that indicate higher risk than the standard calculator estimates. Key risk-enhancing factors include:
- Family history of premature ASCVD (heart attacks or cardiovascular events in male relatives under 55 or female relatives under 65)
- Primary hypercholesterolemia (persistent LDL-C between 160 and 189 mg/dL)
- Chronic Kidney Disease (CKD)
- Metabolic syndrome
- Preeclampsia or premature menopause (before age 40)
- Chronic inflammatory conditions, such as rheumatoid arthritis, psoriasis, lupus, or HIV
- High-sensitivity C-reactive protein (hsCRP) levels of 2.0 mg/L or higher
- Elevated Lipoprotein(a) levels above 50 mg/dL (or 125 nmol/L)
- Elevated apolipoprotein B (ApoB) levels of 130 mg/dL or higher
- Ankle-brachial index (ABI) less than 0.9
💡 💡 The Power of a CAC Score of Zero
In patients at intermediate risk, a Coronary Artery Calcium (CAC) score of zero can help identify individuals who may safely defer statin therapy. This applies unless the patient has high-risk conditions such as diabetes, a strong family history of premature heart disease, or currently smokes.
Coronary Artery Calcium (CAC) Scoring
When treatment decisions remain uncertain after calculating ASCVD risk and reviewing risk-enhancing factors, clinicians may recommend a Coronary Artery Calcium (CAC) scan. A CAC scan is a low-dose, non-contrast chest CT scan that measures calcified plaque in the coronary arteries. The findings are reported as an Agatston score:
- CAC Score of 0: Indicates no calcified plaque is present. Statin therapy can often be deferred for 5 to 10 years, unless high-risk factors like smoking or diabetes are present.
- CAC Score of 1 to 99: Indicates mild plaque. Statin therapy is generally recommended.
- CAC Score of 100 or higher: Indicates significant plaque. High-intensity statin therapy is strongly recommended.
Using ASCVD risk calculators alongside clinical risk-enhancing factors and CAC scans helps personalize cardiovascular prevention strategies.
💡 Frequently Asked Questions (FAQ)
📚 References & Sources
- Grundy SM, et al. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation, 139(25), e1082-e1143.
- Budoff MJ, et al. (2018). Ten-Year Association of Coronary Artery Calcium With Atherosclerotic Cardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis (MESA). Journal of the American College of Cardiology, 72(10), 1083-1091.